Cannabinoids show promise for symptom management in neuromuscular disorders, with the strongest evidence from multiple sclerosis studies on pain and spasticity.
Neurologists, physiatrists, NMD patients, and cannabinoid therapy researchers.
MS evidence strongestfor cannabinoid use in neuromuscular disorders, with emerging data across other NMD types
What the researchers found
Most evidence on cannabinoids for NMDs comes from MS pain and spasticity studies. Preclinical and clinical studies across other NMDs suggest potential benefits, though the evidence base is still developing.
Why it matters
Neuromuscular disorders are currently untreatable, and symptom management options are limited. Cannabinoids could offer an additional therapeutic avenue for pain, spasticity, and other debilitating symptoms.
The numbers in context
Not quantified in abstract; review covers cannabinoids, endocannabinoids, and synthetic cannabimimetics across the spectrum of neuromuscular disorders.
How the study worked
Review article summarizing preclinical and clinical evidence for cannabinoid use in neuromuscular disorders including motor neuron diseases, peripheral neuropathies, and skeletal muscle conditions.
Who was studied
Not applicable (review covering patients with various neuromuscular disorders).
What this study cannot tell us
Review format without systematic methodology. Evidence from MS may not generalize to all NMDs. Many referenced studies are preclinical. Heterogeneity of NMDs limits generalization.
How to read the evidence
Narrative review of heterogeneous evidence; quality ranges from strong RCTs (MS) to preliminary preclinical data (other NMDs).
When this study was published
Recent review summarizing decades of cannabinoid-NMD research.
The bigger picture
This comprehensive review maps the current evidence landscape for cannabinoids in NMDs, identifying where the science is strong (MS) and where significant gaps remain (most other NMDs).
Replication
Review article; primary studies vary in quality and stage of development.
Funding
Not specified in abstract
Conflicts of interest
Not specified in abstract
Questions still open
- Which specific NMDs are most likely to benefit from cannabinoid treatment?
- Can endocannabinoid system modulation slow disease progression or only manage symptoms?
Read the original research
Cannabinoids, Endocannabinoids, and Synthetic Cannabimimetic Molecules in Neuromuscular Disorders.
International journal of molecular sciences, 25(1)
Citation
Iannotti, Fabio Arturo. (2023). Cannabinoids, Endocannabinoids, and Synthetic Cannabimimetic Molecules in Neuromuscular Disorders.. International journal of molecular sciences, 25(1). https://doi.org/10.3390/ijms25010238